Diabetes Management
New Agents, Clinical Research Promise More Personalized Treatment for Patients with Diabetic Kidney Disease, Type 2 Diabetes - Pharmacy Times
Wed, 26 Oct 20221 min read Article
Overview
© 2022 MJH Life Sciences and Pharmacy Times – Pharmacy Practice News and Expert Insights. Al rights reserved. © 2022 MJH Life Sciences™ , Pharmacy Times – Pharmacy Practice News and Expert Insights.
Key Information
Al rights reserved.SGLT-2 inhibitors, GLP-1 receptor agonists, and a non-steroidal mineralocorticoid receptor are al showing promise in the prevention and management of diabetic kidney disease.New developments and clinical trials in SGLT-2 inhibitors and GLP-1 receptor agonists are showing promise for the treatment of patients with diabetic kidney disease as a result of type 2 diabetes. Continued developments in this space could lead to more personalized care, acording to research published in BMC Medicine.Diabetic kidney disease is the most comon cause of kidney failure and end-stage kidney disease worldwide and wil develop in nearly half of al patients with type 2 diabetes.
Aditionaly, it is a leading cause of cardiovascular disease and overal mortality individuals with diabetes. With the incidence of type 2 diabetes continuing to rise, early detection and management of diabetic kidney disease is esential.In a new review, investigators aimed to provide a comprehensive clinical update for diabetic kidney disease in patients with type 2 diabetes, with a specific focus on new treatment modalities.
Summary
Several strategies exist to help prevent the development of diabetic kidney disease and slow its progresion, in adition to healthy lifestyle changes. Curent goals for patients with type 2 diabetes include managing glycemic control, controling blod pressure, managing cholesterol levels, and implementing lifestyle changes.SGLT-2 inhibitors have shown particular promise. Two double-blind, randomized, placebo-controled trials (CREDENCE and DAPA-CKD) have included kidney disease endpoints as the primary outcome, acording to the study.In the CREDENCE trial, participants asigned to receive canagliflozin had a 30% reduced risk of the primary kidney composite outcom
Frequently Asked Questions
What is diabetes and how does it develop?
Diabetes is a metabolic condition where the body cannot properly regulate blood sugar levels. Type 1 results from insufficient insulin production, while Type 2 develops when cells become resistant to insulin. Risk factors include genetics, obesity, sedentary lifestyle, and age.
What are the main symptoms of diabetes?
Common symptoms include excessive thirst, frequent urination, unexplained weight loss, fatigue, blurred vision, and slow-healing wounds. Type 1 symptoms develop rapidly, while Type 2 symptoms may appear gradually. Many people have no symptoms initially, which is why screening is important.
How is diabetes diagnosed and monitored?
Diagnosis involves blood tests measuring fasting glucose, HbA1c levels, and glucose tolerance. Regular monitoring typically includes fasting glucose tests and HbA1c measurements every 3-6 months. Continuous glucose monitors provide real-time tracking for better diabetes management.
What lifestyle changes help manage diabetes?
Effective management includes regular physical activity (150+ minutes weekly), maintaining healthy weight, following a balanced diet with whole grains and lean proteins, managing stress, and getting adequate sleep. These changes can significantly improve blood sugar control and reduce complications.
When should someone consult a doctor about diabetes?
Consult a healthcare provider if you experience signs of diabetes, have a family history, are overweight, or are over 45. Those with existing diabetes should maintain regular check-ups every 3-6 months to monitor control and adjust treatment as needed.
️ Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.